Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

ProKidney Corp.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

KENNETH LOCKE JOINS AS CHIEF TECHNICAL OFFICER, BRINGING MORE THAN 25 YEARS OF EXPERIENCE ACROSS CHEMISTRY, MANUFACTURING AND CONTROLS (CMC) AND SUPPLY CHAIN AS PROKIDNEY PROGRESSES TOWARD THE POTENTIAL COMMERCIALIZATION OF RILPARENCEL KENNETH LOCKE JOINS AS CHIEF TECHNICAL OFFICER, BRINGING MORE THAN 25 YEARS OF EXPERIENCE ACROSS CHEMISTRY, MANUFACTURING AND CONTROLS (CMC) AND SUPPLY CHAIN AS PROKIDNEY PROGRESSES TOWARD THE POTENTIAL COMMERCIALIZATION OF RILPARENCEL

PROKIDNEY APPOINTS KENNETH LOCKE AS CHIEF TECHNICAL OFFICER

WINSTON-SALEM, N.C., MAY 15, 2026 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK)(PROKIDNEY OR THE COMPANY"), A LEADING LATE CLINICAL-STAGE CELL THERAPY COMPANY FOCUSED ON CHRONIC KIDNEY DISEASE (CKD), TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED BUSINESS HIGHLIGHTS.

PROKIDNEY REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

WINSTON-SALEM, N.C., MARCH 25, 2026 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK) (PROKIDNEY OR THE COMPANY"), A LEADING LATE CLINICAL-STAGE CELL THERAPY COMPANY FOCUSED ON CHRONIC KIDNEY DISEASE (CKD), TODAY ANNOUNCED THE APPOINTMENT OF GREG MADISON AS CHIEF COMMERCIAL OFFICER.

PROKIDNEY EXPANDS SENIOR LEADERSHIP TEAM WITH APPOINTMENT OF GREG MADISON AS CHIEF COMMERCIAL OFFICER

WINSTON-SALEM, N.C., JAN. 06, 2026 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK)(PROKIDNEY OR THE COMPANY"), A LEADING LATE CLINICAL-STAGE CELL THERAPY COMPANY FOCUSED ON CHRONIC KIDNEY DISEASE (CKD), TODAY ANNOUNCED THAT PROKIDNEY'S CEO, BRUCE CULLETON, M.D., WILL PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE. THE PROKIDNEY MANAGEMENT TEAM WILL ALSO HOST ONE-ON-ONE MEETINGS THROUGHOUT THE EVENT.

PROKIDNEY TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

WINSTON-SALEM, N.C., NOV. 10, 2025 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK)(PROKIDNEY OR THE COMPANY"), A LEADING LATE CLINICAL-STAGE CELL THERAPY COMPANY FOCUSED ON CHRONIC KIDNEY DISEASE (CKD), TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED REGULATORY AND CLINICAL UPDATES.

PROKIDNEY REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES REGULATORY AND CLINICAL UPDATES

WINSTON-SALEM, N.C., NOV. 06, 2025 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK)(PROKIDNEY OR THE COMPANY"), A LEADING LATE CLINICAL-STAGE CELL THERAPY COMPANY FOCUSED ON CKD, TODAY PRESENTED FULL RESULTS FROM THE PHASE 2 REGEN-007 TRIAL EVALUATING RILPARENCEL IN PATIENTS WITH ADVANCED CKD AND DIABETES. THE DATA, FEATURED IN A LATE-BREAKING CLINICAL TRIALS PRESENTATION AT THE AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK 2025, FURTHER DEMONSTRATE THE POTENTIAL OF RILPARENCEL TO PRESERVE KIDNEY FUNCTION IN PATIENTS WITH ADVANCED CKD AND DIABETES WHO ARE AT HIGH RISK OF KIDNEY FAILURE AND HAVE LIMITED THERAPEUTIC OPTIONS.

PROKIDNEY PRESENTS FULL RESULTS FROM THE PHASE 2 REGEN-007 TRIAL OF RILPARENCEL AT THE AMERICAN SOCIETY OF NEPHROLOGY KIDNEY WEEK 2025

WINSTON-SALEM, N.C., OCT. 29, 2025 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK)(PROKIDNEY OR THE COMPANY"), A LEADING LATE CLINICAL-STAGE CELLULAR THERAPEUTICS COMPANY FOCUSED ON CHRONIC KIDNEY DISEASE (CKD), TODAY ANNOUNCED THAT SENIOR MEMBERS OF THE MANAGEMENT TEAM WILL BE PARTICIPATING IN THE FOLLOWING TWO UPCOMING HEALTHCARE CONFERENCES IN NOVEMBER:

PROKIDNEY TO PARTICIPATE IN TWO UPCOMING CONFERENCES: GUGGENHEIM HEALTHCARE INNOVATION CONFERENCE AND THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

WINSTON-SALEM, N.C., OCT. 20, 2025 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK)(PROKIDNEY OR THE COMPANY"), A LEADING LATE CLINICAL-STAGE CELLULAR THERAPEUTICS COMPANY FOCUSED ON CHRONIC KIDNEY DISEASE (CKD), TODAY ANNOUNCED THAT THE COMPANY WILL PRESENT TWO POSTERS, INCLUDING A LATE-BREAKING POSTER ON THE PHASE 2 REGEN-007 STUDY RESULTS, AT THE UPCOMING AMERICAN SOCIETY OF NEPHROLOGY'S (ASN) KIDNEY WEEK BEING HELD FROM NOVEMBER 6-9, 2025, IN HOUSTON, TX.

PROKIDNEY ANNOUNCES TWO ABSTRACTS SELECTED FOR PRESENTATION AT THE AMERICAN SOCIETY OF NEPHROLOGY'S KIDNEY WEEK 2025

WINSTON-SALEM, N.C., AUG. 12, 2025 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK) (PROKIDNEY OR THE COMPANY"), A LEADING LATE CLINICAL-STAGE CELL THERAPEUTICS COMPANY FOCUSED ON CHRONIC KIDNEY DISEASE (CKD), TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED REGULATORY AND CLINICAL UPDATES.

PROKIDNEY REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES REGULATORY AND CLINICAL UPDATES

WINSTON-SALEM, N.C., JULY 15, 2025 (GLOBE NEWSWIRE) -- PROKIDNEY CORP. (NASDAQ: PROK) (PROKIDNEY OR THE COMPANY"), A LEADING LATE CLINICAL-STAGE CELLULAR THERAPEUTICS COMPANY FOCUSED ON CHRONIC KIDNEY DISEASE (CKD), TODAY ANNOUNCED CONFIRMATION OF ALIGNMENT WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) ON THE ACCELERATED APPROVAL PATHWAY FOR RILPARENCEL. RILPARENCEL IS AN AUTOLOGOUS CELLULAR THERAPY THAT RECEIVED REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FROM THE FDA AND CURRENTLY IS BEING EVALUATED IN THE ONGOING PHASE 3 REGEN-006 (PROACT 1) TRIAL TO DEMONSTRATE THE THERAPY'S POTENTIAL TO PRESERVE KIDNEY FUNCTION IN PATIENTS WITH ADVANCED CKD AND TYPE 2 DIABETES.

ProKidney Corp.

PROK

Price

Financial Reports

No items found.

Press Releases

ProKidney Corp.

PROK.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PROK